Diana Rofail - Concepedia

Author

Diana Rofail

Novartis (United States)ORCID

Also Known As

D Rofail, D. Rofail, DIANA ROFAIL, Diana Rofail

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Regeneron (United States)Adelphi Group (United Kingdom)Novartis (Switzerland)Mapi Research Trust

About

Diana Rofail is an author at Novartis (United States) specializing in medicine, pharmacotherapy, and iron metabolism.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	433
2	Public Health	2	2	59
3	Health Sciences	1	1	63
4	Social Sciences	1	1	19
5	Epidemiology	1	1	40

Diana Rofail

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton, New England Journal of Medicine	2020	1.8K
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia Maria Domenica Cappellini, Mohamed Béjaoui, Leyla Ağaoğlu, Clinical Therapeutics AnemiaPatient-reported OutcomesIron MetabolismIron OverloadHematology	2007	118
A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication Richard Gray, Diana Rofail, Jon Allen, Journal of Advanced Nursing	2005	106
Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA study L Scalone, LG Mantovani, Marieke Krol, Current Medical Research and Opinion	2008	104
Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload Krista Payne, Diana Rofail, Jean‐François Baladi, Advances in Therapy Health EconomicsHealth PolicyIron MetabolismIron OverloadIron Chelation Therapy	2008	72
Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in<i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial John B. Porter, Donald K. Bowden, Marina Economou, Anemia Quality Of LifeFamily MedicineHealth-related QualityIron MetabolismPharmacotherapy	2012	63
Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis Elliott Vichinsky, Zahra Pakbaz, Onyinye Onyekwere, Acta Haematologica	2008	60
Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment Pierre Brissot, Simon Ball, Diana Rofail, Transfusion	2010	57
The development and internal consistency of the Satisfaction with Antipsychotic Medication scale Diana Rofail, Richard Gray, Kevin Gournay Psychological Medicine	2005	47
Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial Alì Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Acta Haematologica Iron MetabolismHematologyPharmacologyOnce-daily Oral DeferasiroxOutcomes Research	2010	46

Page 1